Rasagiline as Adjunct to Levodopa for Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis
Background. Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor used as monotherapy in early Parkinson’s disease and as an adjunct therapy to levodopa in Parkinson’s disease with motor fluctuations. Objectives. This meta-analysis aimed to provide updated evidence on the effica...
Saved in:
Main Authors: | Osamu Kano, Hiroshi Tsuda, Ayako Hayashi, Masaki Arai |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2022/4216452 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease
by: J. Guridi, et al.
Published: (2012-01-01) -
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa
by: Cindy Zadikoff, et al.
Published: (2020-01-01) -
The Parkinson’s Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge
by: Dávid Pintér, et al.
Published: (2019-01-01) -
Synergistic action of propolis with levodopa in the management of Parkinsonism in Drosophila melanogaster
by: Herbert Izo, Ninsiima, et al.
Published: (2020) -
Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease
by: Haruo Nishijima, et al.
Published: (2018-01-01)